Carl Zeiss Meditec Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Markus Weber

Chief executive officer

€1.1m

Total compensation

CEO salary percentage40.8%
CEO tenure3.1yrs
CEO ownershipn/a
Management average tenure4.8yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Carl Zeiss Meditec (ETR:AFX) Might Be Having Difficulty Using Its Capital Effectively

Feb 10
Carl Zeiss Meditec (ETR:AFX) Might Be Having Difficulty Using Its Capital Effectively

More Unpleasant Surprises Could Be In Store For Carl Zeiss Meditec AG's (ETR:AFX) Shares After Tumbling 26%

Jan 10
More Unpleasant Surprises Could Be In Store For Carl Zeiss Meditec AG's (ETR:AFX) Shares After Tumbling 26%

Is Carl Zeiss Meditec AG (ETR:AFX) Potentially Undervalued?

Dec 28
Is Carl Zeiss Meditec AG (ETR:AFX) Potentially Undervalued?

Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Dec 04
Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Carl Zeiss Meditec AG's (ETR:AFX) Share Price Could Signal Some Risk

Nov 19
Carl Zeiss Meditec AG's (ETR:AFX) Share Price Could Signal Some Risk

Some Investors May Be Worried About Carl Zeiss Meditec's (ETR:AFX) Returns On Capital

Sep 19
Some Investors May Be Worried About Carl Zeiss Meditec's (ETR:AFX) Returns On Capital

Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Sep 06
Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 27%?

Aug 23
Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 27%?

At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?

Aug 09
At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?

Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Jul 11
Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled

Jun 10
Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled

Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing

May 26
Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing

Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 11
Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

May 09
Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?

Mar 24
Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?

Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Mar 11
Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Markus Weber's remuneration changed compared to Carl Zeiss Meditec's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

€157m

Sep 30 2024€1m€435k

€179m

Jun 30 2024n/an/a

€203m

Mar 31 2024n/an/a

€261m

Dec 31 2023n/an/a

€277m

Sep 30 2023€1m€426k

€290m

Jun 30 2023n/an/a

€308m

Mar 31 2023n/an/a

€278m

Dec 31 2022n/an/a

€307m

Sep 30 2022€1m€298k

€294m

Compensation vs Market: Markus's total compensation ($USD1.12M) is below average for companies of similar size in the German market ($USD3.00M).

Compensation vs Earnings: Markus's compensation has been consistent with company performance over the past year.


CEO

Markus Weber

3.1yrs

Tenure

€1,067,100

Compensation

Dr. Markus Weber is CEO & Chairman of Management Board of Carl Zeiss Meditec AG from January 01, 2022 and served as its President since January 01, 2022 until December 2022. He joined ZEISS Semiconductor M...


Leadership Team

NamePositionTenureCompensationOwnership
Markus Weber
CEO & Chairman of Management Board3.1yrs€1.07mno data
Justus Wehmer
CFO & Member of the Management Board6.3yrs€784.50kno data
Christian Munster
Head of Global Regulatory & Clinical Affairs2.1yrs€22.50kno data
Stefanie Spanagel
Chief Operating Officerno datano datano data
Sebastian Frericks
Director of Investor Relationsno datano datano data
Eva-Maria Heine
Chief Human Resources Officerno datano datano data
Steven Schallhorn
Chief Medical Officer for Global Ophthalmic Devices8.3yrsno datano data
Andrew Chang
Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec4.9yrsno datano data
Euan Thomson
President of Ophthalmic Devices and Head of the Ophthalmic Devices Strategic & Digital Business Unit4.8yrsno datano data
Magnus Reibenspiess
Head of the Microsurgery Strategic Business Unit - ZEISS Medical Technologyno datano datano data

4.8yrs

Average Tenure

59yo

Average Age

Experienced Management: AFX's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christian Munster
Head of Global Regulatory & Clinical Affairs1.9yrs€22.50kno data
Karl Lamprecht
Chairman of the Supervisory Board4.7yrsno datano data
Michael Kaschke
Honorary Chairman of the Supervisory Board3.8yrs€43.10kno data
Isabel De Paoli
Shareholder Representative Member of Supervisory Board4.7yrs€36.00kno data
Peter Kameritsch
Shareholder Representative Member of the Supervisory Board3.8yrs€55.00kno data
Heike Madan
Employee Representative Member of the Supervisory Board1.9yrs€24.50kno data
Tania von der Goltz
Shareholder Representative Member of the Supervisory Board6.8yrs€43.10kno data
Rene Denner
Employee Representative Deputy Chairman of Supervisory Board5.3yrs€55.60kno data
Stefan Müller
Shareholder Representative Member of Supervisory Boardless than a yearno datano data
Jeffrey Marx
Employee Representative Member of Supervisory Board4.9yrs€38.60kno data
Torsten Reitze
Shareholder Representative Member of Supervisory Board3.8yrsno datano data
Brigitte Koblizek
Employee Representative Member of the Supervisory Board2.9yrs€36.00kno data

3.8yrs

Average Tenure

52.5yo

Average Age

Experienced Board: AFX's board of directors are considered experienced (3.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 03:09
End of Day Share Price 2025/02/20 00:00
Earnings2024/12/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Carl Zeiss Meditec AG is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Scott BardoBerenberg
Julien OuaddourBofA Global Research